In vitro susceptibility of filamentous fungi from mycotic keratitis to azole drugs by Shobana, Coimbatore Subramanian et al.
+ Models
MYCMED-525; No. of Pages 6ORIGINAL ARTICLE/ARTICLE ORIGINAL
In vitro susceptibility of filamentous fungi
from mycotic keratitis to azole drugs
Sensibilite´ in vitro aux azole´s de champignons filamenteux, agents
de ke´ratite fongique
C.S. Shobana a,*, A. Mythili a, M. Homa b, L. Galgóczy b,
R. Priya a, Y.R. Babu Singh a, K. Panneerselvam c,
C. Vágvölgyi b, L. Kredics b, V. Narendran d, P. Manikandan d,e
aDepartment of Microbiology, Dr. G.R. Damodaran College of Science, Avanashi Road, Civil Aerodrome Post,
Coimbatore, 641 014, Tamilnadu, India
b Faculty of Science and Informatics, Department of Microbiology, University of Szeged, Szeged, Hungary
cDepartment of Microbiology, MR Government Arts College, Mannargudi, 614 001, Tamilnadu, India
dDepartment of Microbiology, Aravind Eye Hospital and Post-Graduate institute of Ophthalmology,
Coimbatore, 641 014, Tamilnadu, India
eDepartment of Medical Laboratory, Applied Medical Sciences College, Majmaah University, Saudi Arabia
Received 25 June 2014; received in revised form 29 September 2014; accepted 20 October 2014
KEYWORDS
Mycotic keratitis;
Fungal isolates;
Antifungal susceptibility
and azole drugs
Summary
Objective. — The in vitro antifungal activities of azole drugs viz., itraconazole, voriconazole,
ketoconazole, econazole and clotrimazole were investigated in order to evaluate their efficacy
against filamentous fungi isolated from mycotic keratitis.
Methods. — The specimen collection was carried out from fungal keratitis patients attending
Aravind eye hospital and Post-graduate institute of ophthalmology, Coimbatore, India and was
subsequently processed for the isolation of fungi. The dilutions of antifungal drugs were
prepared in RPMI 1640 medium. Minimum inhibitory concentrations (MICs) were determined
and MIC50 and MIC90 were calculated for each drug tested.
Results. — A total of 60 fungal isolates were identified as Fusarium spp. (n = 30), non-sporulating
moulds (n = 9), Aspergillus flavus (n = 6), Bipolaris spp. (n = 6), Exserohilum spp. (n = 4),
Curvularia spp. (n = 3), Alternaria spp. (n = 1) and Exophiala spp. (n = 1). The MICs of ketocona-
zole, clotrimazole, voriconazole, econazole and itraconazole for all the fungal isolates ranged
between16 mg/mL and 0.03 mg/mL, 4 mg/mL and 0.015 mg/mL, 8 mg/mLand 0.015 mg/mL, 8 mg/mL
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MYCMED-525; No. of Pages 6and 0.015 mg/mL and 32 mg/mL and 0.06 mg/mL respectively. From the MIC50 and MIC90 values, it
could be deciphered that in the present study, clotrimazole was more active against the test isolates
at lower concentrations (0.12—5 mg/mL) when compared to other drugs tested.
Conclusion. — The results suggest that amongst the tested azole drugs, clotrimazole followed by
voriconazole and econazole had lower MICs against moulds isolated from mycotic keratitis.
# 2014 Elsevier Masson SAS. All rights reserved.
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Re´sume´
Objectif. — L’activité antifongique in vitro des azolés à savoir, l’itraconazole, le voriconazole,
le kétoconazole, l’éconazole et le clotrimazole a été étudiée afin d’évaluer leur efficacité
vis-à-vis des champignons filamenteux isolés de kératite mycosique.
Me´thodes. — Les échantillons provenant de patients consultant pour kératite fongique au
Aravind Eye Hospital et au Post-Graduate Institute of Ophthalmology, Coimbatore, en Inde
ont été mis en culture pour recherche de champignons. Les dilutions des antifongiques ont été
réalisées en RPMI 1640. Les concentrations minimales inhibitrices (CMI) ont été déterminées et
les CMI50 et CMI90 ont été calculées pour chaque antifongique étudié.
Re´sultats. — Soixante souches de champignons ont été isolées: Fusarium spp. (n = 30), moi-
sissures ne fructifiant pas (n = 9), Aspergillus flavus (n = 6), Bipolaris spp. (n = 6), Exserohilum
spp. (n = 4), Curvularia spp. (n = 3), Alternaria spp. (n = 1) et Exophiala spp. (n = 1). Les CMI du
kétoconazole, du clotrimazole, du voriconazole, de l’itraconazole et de l’éconazole vis-à-vis de
l’ensemble des isolats fongiques variaient respectivement entre 16 mg/mL et 0,03 mg/mL, 4 mg/
mL et 0,015 mg/mL, 8 mg/mL et 0,015 mg/mL, 8 mg/mL et 0,015 mg/mL et 32 mg/mL et 0,06 mg/
mL. À partir des valeurs des CMI50 et CMI90 que nous avons obtenues, le clotrimazole serait la
molécule la plus active vis-à-vis des isolats étudiés, avec des concentrations (0,12 à 5 mg/mL)
plus faibles que celles des autres antifongiques testés.
Conclusion. — Les résultats suggèrent que, parmi les antifongiques azolés testés, le clotrima-
zole suivi par le voriconazole et l’éconazole avaient les CMI les plus basses vis-à-vis des
moisissures isolées de kératites mycosiques.
# 2014 Elsevier Masson SAS. Tous droits réservés.
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Microbial keratitis is the most common severe ocular infec-
tion and may be caused by a variety of bacteria, fungi
(yeasts, moulds and microsporidia) and protists (e.g. Acan-
thamoeba). It is characterized by an acute or sub-acute
onset of pain, conjunctival injection and corneal ulceration
with a stromal inflammatory infiltrate [42,16,6,36]. Keratitis
due to filamentous fungi is believed to usually occur follow-
ing trauma, the key-predisposing factor, in healthy young
males engaged in agricultural or other outdoor work [8]. The
traumatizing agents can be of plant or animal origin (even
dust particles), that either directly implant fungal conidia in
the corneal stroma, or abrade the epithelium-permitting
invasion by exogenous fungi [41]. The etiologic agents of
mycotic keratitis show a varying pattern with respect to
geographic locality and climatic conditions [7]. More than
105 species of fungi spanning 70 genera have been reported
to cause mycotic keratitis [1]. Of these, Fusarium spp. and
Aspergillus spp. are the most common etiological agents of
corneal ulcerations [2,5,28].
Pujol et al. [32] reported that amphotericin B (AMB) is
probably the most effective drug in vivo, although there have
been many clinical treatment failures. Natamycin, a
tetraene polyene, has long been considered the mainstay
of treatment for filamentous fungal keratitis. Although these
drugs have poor ocular penetration, they have primarily been
useful in cases with superficial corneal infection [29]. AzolesPlease cite this article in press as: Shobana CS, et al. In vitro suscept
Journal De Mycologie Médicale (2014), http://dx.doi.org/10.1016/j.m(imidazoles and triazoles) viz., ketoconazole (KTZ), mico-
nazole (MCZ), fluconazole (FLZ), itraconazole (ITC), econa-
zole (ECN) and clotrimazole (CLT), inhibit fungal ergosterol
biosynthesis at low concentrations, while at higher concen-
trations they appear to cause direct damage to the fungal
cell walls [40]. According to Srinivasan [35], ongoing research
towards rapid diagnosis and specific drug therapy could
minimize the morbidity caused by this preventable disease.
The current knowledge on antifungal susceptibilities is
mainly based on Western literature and local data available
in India pertaining to filamentous fungi other than Fusarium
and Aspergillus are inadequate. The present study was
undertaken to isolate and identify filamentous fungi involved
in mycotic keratitis from the patients attending a tertiary
care eye hospital in Coimbatore, Tamilnadu, India, and to
determine their in vitro susceptibility against five azole
antifungal drugs by employing the Clinical and laboratory
standards institute (CLSI) broth microdilution method M38-
A2 document [9].
Materials and methods
Samples and fungal isolates
This non-randomized study was carried out at Aravind eye
hospital and Post-graduate institute of ophthalmology, Coim-
batore, India. The specimen collection was carried out bet-
ween October 2012 and August 2013. Corneal scrapings wereibility of filamentous fungi from mycotic keratitis to azole drugs.
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In vitro susceptibility of filamentous fungi from mycotic keratitis to azole drugs 3performed under aseptic conditions on each ulcer using a
flame sterilized Kimura’s spatula, after instillation of 4%
preservative free lignocaine (lidocaine) [18]. Material obtai-
ned from scraping the leading edge and the base of the ulcer
was inoculated directly onto 5% sheep’s blood agar (SBA),
chocolate agar (CA) and potato dextrose agar (PDA) (250 g of
potato slices, 15 g agar, 10 g dextrose and 1000 mL distilled
water), as well as into brain heart infusion (BHI) broth without
gentamicin sulphate. SBA base, CA plates and BHI broth were
purchased from Himedia Laboratories, Mumbai, India. Plates
were incubated under aerobic conditions at 37 8C, while the
PDA bottles were incubated at 27 8C for fungal growth, for
72 h. The obtained material was subjected to Gram staining
and 10% potassium hydroxide mount. Any positive fungal
isolate was identified to the genus level and Aspergillus
spp. were identified to the species level based on colony
morphology and lactophenol cotton blue mount preparation
of the fungal cultures employing the cellophane tape flag
method [3,14,24].
In vitro azole susceptibility testing
As per the CLSI guidelines, in every batch of MIC, A. flavus
ATCC 204304 was included as reference strain [9]. All the
fungal isolates were subcultured on SDA plates and incubated
at 30 8C for 7 to 15 days. The inoculum suspension was
prepared by harvesting the spores from mature plates into
sterile distilled water. The spore suspension was then adjus-
ted spectrophotometrically to the required optical density
for each species as outlined in CLSI M38-A2 document [9],
providing an inoculum concentration of 0.4  104 to 5  104
CFU/mL, which was verified by colony count. Further dilu-
tions (1:50) were carried out using RPMI 1640 medium
(Sigma-Aldrich, St. Louis, MO, USA).
The clinically used and commercially available azole
drugs viz., ITC (Sigma-Aldrich, St. Louis, MO, USA), vorico-
nazole (VRC) (Aurolab, Madurai, India), KTZ (Himedia, Mum-
bai, India), ECN (Aurolab, Madurai, India) and CLT (Aurolab,
Madurai, India) were chosen for the present study. The drugs
were dissolved in dimethyl sulfoxide and the dilutions
were prepared in RPMI 1640 in order to achieve a range of
8—0.015 mg/mL (ECN, VRC and CLT), 32—0.06 mg/mL (ITC)
and 16—0.03 mg/mL (KTZ).
For the broth microdilution method, 100 mL of each drug
dilution and 100 mL of the prepared spore suspension were
added into U-bottomed microtiter plate wells. Two separate
wells were maintained, one as growth control (100 mL media
and 100 mL inoculum) and another as sterility control (100 mL
media and 100 mL water). The plates were incubated at 288 C
until growth was visible in growth control. MICs were deter-
mined visually with the aid of a reading mirror and were
defined as the lowest drug concentration that caused 80%
inhibition of the growth in comparison to the growth control.
The MIC50 was taken as the MIC that was the median value and
similarly, the MIC90 was the 90th percentile value and repre-
sented the concentration of drug that would inhibit 90% of
the isolates tested [10].
Results and discussion
Of 108 ocular samples that were processed, a total of 48
isolates of bacteria and 60 isolates of filamentous fungi werePlease cite this article in press as: Shobana CS, et al. In vitro suscept
Journal De Mycologie Médicale (2014), http://dx.doi.org/10.1016/j.mobtained. Each of the positive samples (n = 60) grew only one
mold and mixed infections were not obtained. These filamen-
tous fungal isolates were identified as Fusarium spp. (n = 30),
non-sporulating moulds (n = 9), Aspergillus flavus (n = 6),
Bipolaris spp. (n = 6), Exserohilum spp. (n = 4), Curvularia
spp. (n = 3), Alternaria spp. (n = 1), and Exophiala spp.
(n = 1). In the present study, the common aetiological agents
of corneal ulcers were identified as filamentous fungi rather
than bacteria. Similar results were obtained by Bharathi et al.
[6], Manikandan et al. [24] and Homa et al. [15] in South India.
Leck et al. [22] also reported similar results from South, North
and East India. But other studies from Thailand and Malaysia
reported that the most frequent causative agents of microbial
keratitis were bacteria [34,27].
Many studies reported that among the filamentous fungi,
Fusarium and Aspergillus species were identified as most
common corneal pathogens [23,39,37,33]. The present study
showed that 50% of corneal infections were caused by Fusa-
rium spp., whereas Aspergillus spp. were responsible for
only 10% of fungal corneal infections. Dematiaceous fungi
such as Bipolaris spp., Exserohilum spp., Curvularia spp.,
Alternaria spp. and Exophiala spp. were also isolated in the
present study. Similar incidences of dematiaceous fungal
keratitis have been reported previously [23,39,11]. Nine
(15%) of the obtained 60 fungal isolates were not identifiable
owing to lack of sporulation. Similar to our findings, Srini-
vasan et al. [37] revealed that out of 155 fungal isolates
cultured from 154 corneal ulcers, 47.1% were Fusarium spp.,
16.1% were Aspergillus spp., and the remaining organisms
were a diverse mixture of unusual fungal pathogens including
a large number of unidentified dematiaceous (13.5%) and
hyaline (9.6%) fungal species.
The commonly used antifungal medications in the treat-
ment of fungal keratitis include polyenes (natamycin and
AMB) and azoles (KTZ, FLZ, ITC and ECN). However, it is
difficult to widely use topical natamycin due to its high price
[43]. Fusarium and Aspergillus strains are quite sensitive to
AMB, but poor penetration into corneas and obvious simu-
lative symptoms make its topical preparation unsuitable to
be administered with a large dosage and for a long-time [43].
Azoles, most commonly FLZ and ITC [4,21] are often chosen
as the combined medications to reduce the toxicity and side
effects of AMB.
The MIC50 and MIC90 of the azole drugs tested for various
fungal isolates are shown in Table 1. CLT was the most
effective antifungal drug against all the isolates tested
except for the NSM, for which ITC was notably active. CLT
was the only drug that was most active against (1—4 mg/mL)
fusaria. VRC, ECN and CLT (0.015—0.5 mg/mL) followed by
ITC (0.25—0.5 mg/mL) were more promising against A. flavus
isolates. Bipolaris isolates were inhibited effectively by
certain concentrations of CLT and ECN in the range of
0.125—1 mg/mL. Exserohilum isolates were inhibited by
CLT and VRC in the concentration range of 0.03—2 mg/mL.
In comparison with other drugs, VRC and CLT showed the
lowest MIC range (0.125—0.25 mg/mL) for Curvularia isola-
tes.
The ability to inhibit fungal isolates at such low concen-
tration shows that CLT could be used in the first-line therapy
of mycotic keratitis. However, Manikandan et al. [24] repor-
ted the requirement of a higher concentration of CLT against
Aspergillus spp. compared to the present study. It is notableibility of filamentous fungi from mycotic keratitis to azole drugs.
ycmed.2014.10.024
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Table 1 In vitro susceptibility of filamentous fungi isolated from keratomycosis to azole drugs.
Sensibilite´ in vitro des champignons filamenteux isole´s de ke´ratomycose aux me´dicaments azole´s.
Agents Groups MIC rangea
(mg/mL)
MIC50
b
(mg/mL)
MIC90
c
(mg/mL)
GMd
(mg/mL)
CLT Fusarium spp. 1—4 4 4 3.134
Non-sporulating molds 0.25—4 1 2 1.166
Aspergillus flavus 0.015—0.5 0.125 0.5 0.156
Bipolaris spp. 0.125—1 0.125 0.5 0.197
Exserohilum spp. 0.03—2 0.12 2 0.205
Curvularia spp. 0—0.25 0.25 0.25 0.25
Alternaria spp. — — — —
Exophiala spp. — — — —
ECN Fusarium spp. 2—8 4 8 5.401
Non-sporulating molds 0.125—4 2 4 0.85
Aspergillus flavus 0.015—0.5 0.5 0.5 0.248
Bipolaris spp. 0.25—1 0.5 1 0.5
Exserohilum spp. 0.06—4 0.06 4 0.244
Curvularia spp. 0—0.5 0.5 0.5 0.5
Alternaria spp. — — — —
Exophiala spp. — — — —
KTZ Fusarium spp. 8—16 16 16 13.928
Non-sporulating molds 0.25—2 1 2 0.925
Aspergillus flavus 0.25—2 2 2 1.259
Bipolaris spp. 0.125—4 0.5 1 0.629
Exserohilum spp. 0.03—8 0.125 8 0.416
Curvularia spp. 1—2 1 2 1.259
Alternaria spp. — — — —
Exophiala spp. — — — —
ITC Fusarium spp. 16—32 32 32 31.269
Non-sporulating molds 0.06—1 1 1 0.460
Aspergillus flavus 0.25—0.5 0.25 0.25 0.280
Bipolaris spp. 0.25—8 0.25 0.5 0.561
Exserohilum spp. 0.06—32 0.06 32 0.471
Curvularia spp. 0.25—0.5 0.5 0.5 0.396
Alternaria spp. — — — —
Exophiala spp. — — — —
VRC Fusarium spp. 1—8 4 8 4
Non-sporulating molds 0.25—8 2 8 1.851
Aspergillus flavus 0.015—0.5 0.125 0.125 0.110
Bipolaris spp. 0.06—4 0.25 0.25 0.278
Exserohilum spp. 0.06—2 0.06 2 0.205
Curvularia spp. 0.125—0.25 0.25 0.25 0.198
Alternaria spp. — — — —
Exophiala spp. — — — —
MIC: minimum inhibitory concentration; Antifungal agents: CLT: clotrimazole; ECN: econalole; KCN: ketoconazole; ITC: itraconazole; VRC:
voriconazole.
a Interval between the lowest and highest MICs.
b Minimum inhibitory concentration median of the antifungal agent.
c Minimum concentration of the antifungal agent 90th percentile.
d Geometric mean of MICs.
4 C.S. Shobana et al.that Fusarium strains were susceptible to ECN at a lower MIC
similar to the reports of Galarreta et al. [12]. The present
findings revealed that, Fusarium spp. and Exophiala spp. were
resistant to VRC and hence higher concentration of drug is
required for the effective treatment. However, there are
studies that have suggested that VRC may have a broader
antifungal spectrum [19,20]. Similar to our findings, Lalitha
et al. [17] and Iqbal et al. [31] stated that Fusarium spp.Please cite this article in press as: Shobana CS, et al. In vitro suscept
Journal De Mycologie Médicale (2014), http://dx.doi.org/10.1016/j.mhad highest MICs to VRC. Prajna et al. [25] reported that
monotherapy with topical voriconazole cannot be recommen-
ded for filamentous fungal keratitis. Additionally, there are
reports of intraocular VRC to be safe in vitro and in vivo and less
toxic to the retina than AMB [26,13]. Pfaller et al. [30] reported
that ITC exerts negligible activity against Fusarium spp. and it
has also been stated that ITC has seldom been administered for
Fusarium infections with non-univocal results [38].ibility of filamentous fungi from mycotic keratitis to azole drugs.
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In vitro susceptibility of filamentous fungi from mycotic keratitis to azole drugs 5Our results indicated that higher concentration of ITC and
KTZ was required for the inhibition of the involved filamentous
fungal isolates, and based on the data obtained, CLT followed
by VRC and ECN are the suggested antifungal agents for the
first-line therapy of human keratomycoses caused by filamen-
tous species. In addition, this study has generated MIC data for
sparingly tested filamentous fungi such as Alternaria spp.,
Bipolaris spp., Curvularia spp., Exserohilum spp. and Exo-
phiala spp.
Conclusion
Overall, the determination of MICs of the investigated five-
azole antifungal drugs against the filamentous fungi causing
keratitis was useful in understanding the efficacy of increa-
sed concentrations of the drugs in inhibiting fungal growth.
The present study observed a variation in the overall activity
of the azole drugs depending on the type of the fungal
species and the drug concentration. Due to the fact that
the practice of subjecting fungal isolates to antifungal sus-
ceptibility tests is uncommon across the diagnostic micro-
biology laboratories in India, and that the susceptibility
pattern is depending from the involved fungus as well as
the nature and concentration of the applied drug, it is further
emphasized that the isolates should compulsorily be exami-
ned for their susceptibility to ensure an accurate therapy.
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